Progenics Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Progenics Pharmaceuticals, Inc.
Calliditas Eyes Full Approval For Tarpeyo In IgAN After Positive Pivotal Update
Data from part B of the Swedish firm’s pivotal trial of Tarpeyo in the rare kidney disorder showed that the treatment effects lasted two years across the entire population, enabling the move from conditional to full approvals in several markets.
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
Organs On Chips: The Primer Is Ready, But The Bullet Will Take Time To Fire
In the first part of this two-part series, In Vivo discussed the potential for organs on chips to revolutionize drug development. However, great challenges wait for developers of the technology.
Travere’s Filspari US Approval Marks First For IgAN
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
- Artificial Intelligence
Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.